K. Azuma

Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study

Antonio Passaro, Jing Wang, Yan Wang et al. · Annals of Oncology · 2023 · 396 citations · Full text

Medicine, Oncology, Pharmacology +17

A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study)

Hiroshige Yoshioka, K. Azuma, Nobuyuki Yamamoto et al. · Annals of Oncology · 2015 · 117 citations · Full text

Medicine, Oncology, Pharmacology +16

Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA

Enriqueta Felip, Byoung Chul Cho, Adlinda Alip et al. · Annals of Oncology · 2024 · 81 citations · Full text

Medicine, Oncology, Pharmacology +17

Prognostic Factors and Efficacy of First-Line Chemotherapy in Patients with Advanced Thymic Carcinoma: A Retrospective Analysis of 286 Patients from NEJ023 Study

Ryo Ko, Takehito Shukuya, Yusuke Okuma et al. · The Oncologist · 2018 · 29 citations · Full text

Medicine, Oncology, Chemotherapy +9

Clinical Practice in Management of Hydration for Lung Cancer Patients Receiving Cisplatin-based Chemotherapy in Japan: A Questionnaire Survey

Kazuhiko Yamada, Tsukasa Yoshida, Yoshio Zaizen et al. · Japanese Journal of Clinical Oncology · 2011 · 14 citations · Full text

Medicine, Oncology, Pharmacology +11